...
首页> 外文期刊>Neurosurgery >Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.
【24h】

Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.

机译:in对流增强人体内交付后g-二亚乙基三胺五乙酸与高分子量分子的共定位。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Convection-enhanced delivery (CED) permits site-specific therapeutic drug delivery within interstitial spaces at increased dosages through circumvention of the blood-brain barrier. CED is currently limited by suboptimal methodologies for monitoring the delivery of therapeutic agents that would permit technical optimization and enhanced therapeutic efficacy. OBJECTIVE: To determine whether a readily available small-molecule MRI contrast agent, gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA), could effectively track the distribution of larger therapeutic agents. METHODS: Gd-DTPA was coinfused with the larger molecular tracer, I-labeled human serum albumin (I-HSA), during CED of an EGFRvIII-specific immunotoxin as part of treatment for a patient with glioblastoma. RESULTS: Infusion of both tracers was safe in this patient. Analysis of both Gd-DTPA and I-HSA during and after infusion revealed a high degree of anatomical and volumetric overlap. CONCLUSION: Gd-DTPA may be able to accurately demonstrate the anatomic and volumetric distribution of large molecules used for antitumor therapy with high resolution and in combination with fluid-attenuated inversion recovery (FLAIR) imaging, and provide additional information about leaks into cerebrospinal fluid spaces and resection cavities. Similar studies should be performed in additional patients to validate our findings and help refine the methodologies we used.
机译:背景:对流增强输送(CED)可以通过规避血脑屏障,以增加的剂量在间隙空间内进行定点治疗药物输送。 CED目前受到用于监测治疗剂递送的次优方法的限制,这将允许技术优化和增强的治疗功效。目的:为了确定现成的小分子MRI造影剂contrast-二乙烯三胺五乙酸(Gd-DTPA)是否可以有效追踪较大治疗剂的分布。方法:在CED EGFRvIII特异性免疫毒素的CED期间,Gd-DTPA与较大分子示踪剂,I标记的人血清白蛋白(I-HSA)共融合,作为胶质母细胞瘤患者治疗的一部分。结果:两种示踪剂的输注在该患者中是安全的。输注期间和之后对Gd-DTPA和I-HSA的分析均显示高度的解剖和体积重叠。结论:Gd-DTPA可以高分辨率准确地证明用于抗肿瘤治疗的大分子的解剖学和体积分布,并结合液衰减倒置恢复(FLAIR)成像,并提供有关漏入脑脊液空间的其他信息和切除腔。应该在其他患者中进行类似的研究,以验证我们的发现并帮助完善我们使用的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号